Appropriate dosing of pilsicainide hydrochloride in patients on hemodialysis

Nephron. 2001 Jun;88(2):134-7. doi: 10.1159/000045973.


Appropriate dosing of pilsicainide hydrochloride, an anti-arrhythmic drug excreted via the kidney, was investigated in patients on dialysis. Ten chronic hemodialysis patients with coexisting severe palpitation of supraventricular premature contractions (SVPC) were treated with 25 mg of pilsicainide hydrochloride before dialysis. All of their plasma concentrations were maintained within the therapeutic range and their mean dialysis rate was 32%. After 2 weeks, 7 patients were followed with consecutive daily dose treatment. In 3 of them, the dosage was returned to the single pre-dialysis administration because of the elevated plasma concentration reaching the toxic range 1 month after the start of administration. The dose schedule was maintained, and plasma pilsicainide concentrations remained within the therapeutic range during the 6-month follow-up. No abnormal findings were found in any parameters of electrocardiography, echocardiography or biochemistry. The number of SVPC diminished > 90% compared to the pretreatment level.

MeSH terms

  • Anti-Arrhythmia Agents / administration & dosage*
  • Anti-Arrhythmia Agents / blood
  • Anti-Arrhythmia Agents / therapeutic use
  • Arrhythmias, Cardiac / complications
  • Arrhythmias, Cardiac / drug therapy
  • Atrial Premature Complexes / drug therapy
  • Atrial Premature Complexes / physiopathology
  • Echocardiography
  • Electrocardiography, Ambulatory
  • Female
  • Humans
  • Kidney Failure, Chronic / complications
  • Lidocaine / administration & dosage*
  • Lidocaine / analogs & derivatives*
  • Lidocaine / blood
  • Lidocaine / therapeutic use
  • Male
  • Middle Aged
  • Renal Dialysis*


  • Anti-Arrhythmia Agents
  • Lidocaine
  • pilsicainide